Buruli Ulcer in Australia, 2008
Total Page:16
File Type:pdf, Size:1020Kb
WHO ANNUAL MEETING ON BURULI ULCER 31 March – 2 April 2009 ABSTRACTS 1 © World Health Organization 2009 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication. Printed by the WHO Document Production Services, Geneva, Switzerland 2 Table of Contents AGENDA - Common and Control Sessions ........................................................................................... 7 AGENDA - Research Session................................................................................................................. 10 ABSTRACTS - Common and Control Sessions................................................................................... 13 An overview of the effort to improve control of Buruli ulcer in Benin..................................................... 15 Roch Christian Johnson Buruli ulcer in Australia, 2008................................................................................................................. 16 Paul Johnson Mycobacterium ulcerans infection in 2008 in French Guyana; HIV immune restoration syndrome; increasing use of two drug therapy rifampicin-clarithromycin treatment................................................ 17 Pierre Couppié Overview of Buruli ulcer control activities in Togo in 2008 ................................................................... 18 Salomon Hainga Summary of the presentation by Cameroon.............................................................................................. 19 Charles Nsom Mba and Ernest Njih National programme presentation, 2009, Ghana ..................................................................................... 20 Edwin Ampadu Buruli ulcer situation in Côte d’ivoire: Activity overview 2008 ............................................................... 23 Henri Assé Democratic Republic of the Congo (DRC): National Buruli Ulcer Control Programme (PNLUB): Annual report for 2008 ............................................................................................................................. 25 Kapay Kibadi Anatole Buruli ulcer in Gabon: an overview of four years' work .........................................................................27 Louis Bayonne Manou Current situation of Buruli ulcer in Congo............................................................................................... 29 Damas Obvala Annual Report on the activities of the National Buruli Ulcer Control Programme (PNLUB) in 2008 .... 30 Kesso Bah Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.................................................................................. 35 Baohong Ji Comparison of rifapentine and rifampicin based oral regimens in treatment of experimental M. ulcerans disease using the kinetic mouse model..................................................................................................... 36 Almeida Deepak Dynamics of serum neopterin concentration during antibiotic treatment of Buruli ulcer disease: evidence of macrophage activation ......................................................................................................................... 38 Steven Sarfo Analysis of histopathological changes and local immune responses in the course of R/S chemotherapy in the experimental Buruli ulcer mouse model ............................................................................................. 40 Marie-Thérèse Ruf Severe multifocal form of Buruli ulcer after streptomycin and rifampicin treatment: a case report with comments on possible dissemination mechanisms.................................................................................... 41 Ange Dossou Preliminary results of a clinical trial of eight-week daily treatment with the combination rifampin- clarithromycin for patients with Buruli ulcer .......................................................................................... 42 Annick Chauty and Baohong Ji Prognostic indicators associated with the clinical response after four weeks of treatments of suspected Buruli ulcer cases with streptomycin and rifampicin in Allada................................................................ 44 Ghislain Emmanuel Sopoh 3 Response to treatment with the combination rifampicin-streptomycin for 5 days per week for 8 weeks for Buruli ulcer............................................................................................................................................... 45 Richard Phillips Antimicrobial treatment for Buruli ulcer: results of the Burulico trial evaluation of a switch to oral treatment to reduce streptomycin injections for early, limited buruli ulcer ............................................. 47 Tjip van der Werf Patterns of healing and paradoxical reactions during antimicrobial treatment of Buruli ulcer - Data from the Burulico drug trial in Ghana...................................................................................................... 49 Wilhelmina Nienhuis The value of diagnosis of M. ulcerans infection by Fine Needle aspiration............................................ 51 Viviane Cassisa Confirmation of cases of Buruli ulcer at the National Buruli Ulcer Reference Laboratory (LNRUB) of the Institut National de Recherche Biomédicale (INRB-Kinshasa) in the Democratic Republic of the Congo .................................................................................................................................................................. 52 Anatole Kapay Kibadi Buruli ulcer molecular diagnosis routinely performed in Cotonou, Benin.............................................. 54 Affolabi Dissou Confirmation of Buruli ulcer in Central African Republic ....................................................................... 55 Fanny Minime-Lingoupou Overview and prospect for the National Buruli Ulcer Reference Centre (CNR-BURULI) in the Buruli ulcer control effort in Côte d’Ivoire......................................................................................................... 56 Aka N'Guetta Outcomes of two evaluations on Buruli ulcer supported by ANESVAD Foundation in Benin and Ghana in 2008 .......................................................................................................................................................... 57 Almudena Morante Méndez Collaboration between the Fondation Luxembourgeoise Raoul Follereau and Benin............................. 58 Emile China A report on volunteer actions for Buruli ulcer children by SCOBU......................................................... 59 Yuki Shimomura Health Foundation Of Ghana................................................................................................................... 60 Lynda Arthur Buruli Ulcer project at Akonolinga .......................................................................................................... 62 Eric Comte, François Sihom Integration of Buruli ulcer control activities into primary health care: the case of the control programme of the Institut Médical Evangélique (IME)/Kimpese in the Democratic Republic of the Congo (DRC)... 63 Bofunga Bosongo Imposo Decentralization at Akonolinga................................................................................................................ 64 Felix Sagno Organization of case management for Buruli ulcer patients in Kouilou department in the Republic of the Congo ....................................................................................................................................................... 65 Jean-Martin Mabiala Three years of implementation of early detection activities in Amansie West District, Ghana ............... 66 Joseph Adomako Early case detection and management of Buruli ulcer cases in the Upper Denkyira